Synapse Signs an Agreement with Pfizer in Oncology Precision Medicine

 Synapse Signs an Agreement with Pfizer in Oncology Precision Medicine

Synapse Signs an Agreement with Pfizer in Oncology Precision Medicine

Shots:

  • Pfizer and Synapse collaborate to advance the cancer outcomes research using real-world evidence and accelerate new cancer therapies for the improvement of patient’s health with an initial focus on molecular testing and therapy choices in precision oncology in the healthcare
  • The focus of the collaboration is to better understand the treatments for people living with cancer and develop evidence-based insights to improve cancer outcomes
  • Syapse’s insights platform, data sharing network and industrial partnerships bring leading healthcare innovators into a unified ecosystem providing access to personalized care regardless of location or income

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post